Pharmaceutical and biotech firms are racing to find treatments and vaccines for severe acute respiratory syndrome (SARS), but they worry that by the time they come up with an actual product, the virus may not be the health crisis it appears to be today.
"To be competitive, you need to get into this fast and work fast," said Gordon Cameron, president and chief financial officer of Acambis Inc, the firm supplying small pox vaccine for a national stockpile. "We're certainly looking at SARS. But we're still trying to figure out what the market will be and what the technical hurdles might be. We have to decide shortly. In the next couple months, we either have a program or we don't."
Despite the urgency, much uncertainty remains. Scientists identified the virus causing SARS just a month ago. SARS has infected more than 5,400 people and killed more than 350 since it first appeared in China late last year. But no one knows how fast or how far the virus will spread.
PHOTO: AFP
Few infectious disease specialists believe SARS will disappear. But they can't predict whether SARS will turn into an epidemic, wax and wane with the seasons like the common cold, or remain a relatively rare illness. Even in a best-case scenario, a vaccine or treatment is years away and by the time it is available, many firms worry the sense of urgency may have faded and too few people will want to be vaccinated to justify the hundreds of millions of dollars it takes to develop a drug or a vaccine.
The drug industry is seeking assurances from various federal health agencies that they will streamline the testing process and buy large quantities if a SARS vaccine pans out. Drug companies say they are willing to take the risk for now because the early research into a drug or vaccine is the least expensive part of the process. But developing, testing and then gaining regulatory approval to get a drug to market can cost hundreds of millions of dollars.
"We're not looking for risk-free, nothing we do is risk-free," said Len Lavenda, a spokesman for Aventis Pasteur, the world's biggest vaccine maker, based in Lyon, France. "But we are looking for assurance the government is going to be there in five years."
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the agency is exploring various options for funding research and partnering with industry. But, he said, it is not yet clear that the government would promise to buy a successful vaccine.
The hurdles in developing vaccines are even more considerable than with other types of drugs. Since they are given to healthy people, they must be safer than most other medications. They are often tested in tens of thousands of patients to ferret out uncommon side effects before reaching the market.
Even then problems arise. A vaccine for rotavirus, a stomach illness that kills a million children worldwide each year, was tested in 10,000 infants in 27 clinical trials over 15 years before it was approved. After all that, a rare side effect only emerged later, causing the vaccine to be pulled off the market.
But the industry is plowing ahead. Pharmaceutical giant Merck and Co, based in Whitehouse Station, New Jersey, is screening its stable of drugs to see if any of them will help treat SARS. Merck asked the government for a copy of the virus and dozens of its researchers are beginning work to discover a vaccine.
Chiron Corp, an Emeryville, California, biotech, deciphered the genetic code of one strain of the SARS virus and has 15 scientists searching for a vaccine.
GenVec Inc, a Gaithersburg, Maryland, firm, teamed up with government scientists to hunt for a vaccine based on the same technology it is using to develop an HIV vaccine. GenVec already had a US$10 million contract with the National Institute of Health's (NIH) Vaccine Research Center to work with federal scientists on an AIDS vaccine. As more was learned about the SARS virus, Paul Fischer, GenVec's president and chief executive, suspected its vaccine technology might also be applied to SARS.
That afternoon, GenVec researchers began brainstorming with colleagues at NIH to put together a work plan. Two weeks later, GenVec and NIH hammered out a modified contract in which NIH gave another US$420,000 to start a SARS program. Fischer expects the collaboration to begin making various experimental vaccines in coming weeks that can be tested in animals. If the researchers get lucky, Fischer said, a vaccine could begin human testing in a year.
"In the best of all possible worlds, this virus dies out quickly," Fischer said. "But most people think it will probably return as a seasonal virus. The worst case is that it becomes a terrible epidemic worldwide. In either of the last two scenarios, speed is key."
The history of vaccine development is filled with research efforts that take years to bear fruit. In the 1980s, when researchers first set out to discover a vaccine for HIV, they hoped to have one in hand in a few years. Now, nearly 20 years later, several HIV vaccines are in clinical trials but none has yet reached the market.
Another company in the race is Medarex Inc. Based in Princeton, New Jersey, it joined forces with state researchers in Jamaica Plain and Worcester in search of a molecule that would specifically target the virus and prevent infection in those exposed to the disease.
Dr. Donna Ambrosino, director of the Massachusetts Biologics Lab in Jamaica Plain, part of the University of Massachusetts Medical School, approached Medarex earlier this month with an idea she hopes could control outbreaks of SARS. The state lab was working with Medarex for more than a year on another project. The company genetically engineers mice to produce monoclonal antibodies, hailed as the body's version of guided missiles for their ability to seek out and destroy specific disease-causing cells. In some cases, monoclonal antibody therapies have been easier to develop than vaccines.
"Vaccines are just tough," Ambrosino said. "When you get one that works, it's the best approach. But it takes a long time. That doesn't mean we shouldn't start today. But that's why I feel our effort also needs to begin now."
RETHINK? The defense ministry and Navy Command Headquarters could take over the indigenous submarine project and change its production timeline, a source said Admiral Huang Shu-kuang’s (黃曙光) resignation as head of the Indigenous Submarine Program and as a member of the National Security Council could affect the production of submarines, a source said yesterday. Huang in a statement last night said he had decided to resign due to national security concerns while expressing the hope that it would put a stop to political wrangling that only undermines the advancement of the nation’s defense capabilities. Taiwan People’s Party Legislator Vivian Huang (黃珊珊) yesterday said that the admiral, her older brother, felt it was time for him to step down and that he had completed what he
Taiwan has experienced its most significant improvement in the QS World University Rankings by Subject, data provided on Sunday by international higher education analyst Quacquarelli Symonds (QS) showed. Compared with last year’s edition of the rankings, which measure academic excellence and influence, Taiwanese universities made great improvements in the H Index metric, which evaluates research productivity and its impact, with a notable 30 percent increase overall, QS said. Taiwanese universities also made notable progress in the Citations per Paper metric, which measures the impact of research, achieving a 13 percent increase. Taiwanese universities gained 10 percent in Academic Reputation, but declined 18 percent
BULLY TACTICS: Beijing has continued its incursions into Taiwan’s airspace even as Xi Jinping talked about Taiwan being part of the Chinese family and nation China should stop its coercion of Taiwan and respect mainstream public opinion in Taiwan about sovereignty if its expression of goodwill is genuine, the Ministry of Foreign Affairs (MOFA) said yesterday. Ministry spokesman Jeff Liu (劉永健) made the comment in response to media queries about a meeting between former president Ma Ying-jeou (馬英九) and Chinese President Xi Jinping (習近平) the previous day. Ma voiced support for the so-called “1992 consensus,” while Xi said that although the two sides of the Taiwan Strait have “different systems,” this does not change the fact that they are “part of the same country,” and that “external
UNDER DISCUSSION: The combatant command would integrate fast attack boat and anti-ship missile groups to defend waters closest to the coastline, a source said The military could establish a new combatant command as early as 2026, which would be tasked with defending Taiwan’s territorial waters 24 nautical miles (44.4km) from the nation’s coastline, a source familiar with the matter said yesterday. The new command, which would fall under the Naval Command Headquarters, would be led by a vice admiral and integrate existing fast attack boat and anti-ship missile groups, along with the Naval Maritime Surveillance and Reconnaissance Command, said the source, who asked to remain anonymous. It could be launched by 2026, but details are being discussed and no final timetable has been announced, the source